# A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)

> **NCT06829199** · PHASE2 · WITHDRAWN · sponsor: **Merck Sharp & Dohme LLC**

## Conditions studied

- Early Triple Negative Breast Cancer

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** Doxorubicin (hydrochloride)
- **BIOLOGICAL:** Boserolimab
- **DRUG:** Epirubicin Hydrochloride
- **DRUG:** Cyclophosphamide
- **DRUG:** Capecitabine
- **DRUG:** Olaparib (if approved/available locally)

## Key facts

- **NCT ID:** NCT06829199
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-03-26
- **Primary completion:** 2029-01-18
- **Final completion:** 2031-03-18
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Since patients were not recruited yet, we would mark this as a Withdrawn status per the NIH definition of that status. Study halted prematurely, prior to enrollment of first participant.
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06829199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06829199, "A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06829199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*